Skip to Content
scroll

Healius (HLS) $4.68

FY21 Result: The result today were marginally lower than consensus expectations however the year on year growth was impressive all the same, a clear COVID beneficiary that is playing a key role in testing & pathology. The market looks forward and clearly the outlook for FY22 is for slower growth and it seemed like that was the focus today. Not a stock we own however the ~7% pullback today has us reviewing more closely.

chart
image description
Healius (HLS)
image description

Relevant suggested news and content from the site

Back to top